Menu
Global B2B sourcing platform
Verified suppliers and manufacturers

99% High Assay Anti-Rheumatism Pharmaceutical Baricitinib CAS 1187594-09-7

Price $100.00
Min Order 1 gram
Availability In Stock
Shipping From Shaanxi, China
Popularity 447 people viewed
Model NO.:
Frazer-Baricitinib
Powder:
Yes
Customized:
Customized
Certification:
GMP, HSE, ISO 9001, USP, BP
Suitable for:
Elderly, Children, Adult
State:
White Powder
Purity:
>99%
Appearance:
White Powder
CAS No:
1187594-09-7
Shelf Life:
2 Years
Test Method:
HPLC
Storage:
Store Cool Dry Place
Resource:
Natural
Quality Requirement:
Strictly Quality Control
Market:
Worldwide
Service:
Welcome to Visit Us
Delivery Time:
7-10days
Mf:
C16h17n7o2s
Trademark:
Xi'an Frazer Biotech Co., Ltd.
Transport Package:
Foil Bag
Specification:
99%
Origin:
China
Product Description
99% High Assay Anti-Rheumatism Pharmaceutical Baricitinib 1187594-09-7


Specification of Analysis

 
ItemsStandardsResults
AppearanceWhite or off-white solid powderComplies
IdentificationBy IRComplies
 By HPLCComplies
SolubilitySoluble in DMSO, sparingly soluble in THF and Ace tone, slightly soluble in meth anol,  and 0.1N HCl, very sightly soluble in ethanol and dichlo romethane, practically insoluble in waterComplies
Melting Point213.0ºC~215.0ºC213.1ºC~214.6ºC
Water Content≤ 0.50%0.08%
Heavy Metals≤ 20ppmComplies
Residue on Ignition≤ 0.20%0.08%
Relative SubstanceAny single impurity: ≤0.10%0.07%
 Total Impurities: ≤1.00%0.18%
Assay                  (on the anhydrous basis)98.0%~102.0%99.90%
Particle SizeD90: ≤60µmComplies
Reference StandardIn-house Standard
ConclusionThe product complied to In-house standard.
StoragePreserve in tight,light-resistant containers in a cool place


Description: 

Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved for use in the European Union and the United States.

Indications

1. It is used for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. Patients with intolerance to one or more anti-rheumatic drugs can be treated with this product. This product can be treated as a single agent or combined with a Combined treatment of methotrexate in Chemicalbook therapy. The efficacy of baricitinib in the treatment of psoriasis, diabetic nephropathy, atopic dermatitis, systemic lupus erythematosus and other diseases is currently in phase II clinical stage.
2. Used in the field of scientific research and chemical reagent.

  • Similar Products
Full Page Contact Supplier